Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg

Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · see citing works

Functions of DNA methylation: islands, start sites, gene bodies and beyond

Jones, P. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3230 · Cited by 6,061 · see citing works

Hepatocellular Carcinoma

Villanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508 · see citing works

Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma

Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490 · see citing works

Epidemiology of Hepatocellular Carcinoma

McGlynn, K. A., Petrick, J. L., & El‐Serag, H. B. (2020) · Hepatology · doi:10.1002/hep.31288 · Cited by 2,200 · see citing works

Hepatocellular Carcinoma.

(1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-5-642_1 · Cited by 2,087 · see citing works

Molecular therapies and precision medicine for hepatocellular carcinoma

Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,948 · see citing works

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3252 · Cited by 1,803 · see citing works

TET-mediated active DNA demethylation: mechanism, function and beyond

Wu, X., & Zhang, Y. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.33 · Cited by 1,661 · see citing works

The DNA methyltransferase family: a versatile toolkit for epigenetic regulation

Lyko, F. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.80 · Cited by 1,475 · see citing works

Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma

Guichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Benmaad, I., Caldéraro, J., Bioulac‐Sage, P., Letexier, M., Degos, F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2256 · Cited by 1,451 · see citing works

Epigenetic plasticity and the hallmarks of cancer

Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340 · see citing works

Genetic landscape and biomarkers of hepatocellular carcinoma

Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325 · see citing works

Writing, erasing and reading histone lysine methylations

Hyun, K., Jeon, J., Park, K., & Kim, J. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.11 · Cited by 1,250 · see citing works

Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer

Yang, X., Han, H., De Carvalho, D. D., Lay, F. D., Jones, P. A., & Liang, G. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.028 · Cited by 1,199 · see citing works

Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma

Gao, Q., Zhu, H., Dong, L., Shi, W., Chen, R., Song, Z., Huang, C., Li, J., Dong, X., Zhou, Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.052 · Cited by 1,096 · see citing works

Role of TET enzymes in DNA methylation, development, and cancer

Rasmussen, K. D., & Helin, K. (2016) · Genes & Development · doi:10.1101/gad.276568.115 · Cited by 1,040 · see citing works

DNA methylation pathways and their crosstalk with histone methylation

Du, J., Johnson, L. M., Jacobsen, S. E., & Patel, D. J. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4043 · Cited by 1,000 · see citing works

Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators

Fujimoto, A., Totoki, Y., Abe, T., Boroevich, K. A., Hosoda, F., Hà, N. H., Aoki, M., Hosono, N., Kubo, M., Miya, F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2291 · Cited by 868 · see citing works

Trans-ancestry mutational landscape of hepatocellular carcinoma genomes

Totoki, Y., Tatsuno, K., Covington, K. R., Ueda, H., Creighton, C. J., Kato, M., Tsuji, S., Donehower, L. A., Slagle, B. L., Nakamura, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.3126 · Cited by 781 · see citing works

Lateral Thinking: How Histone Modifications Regulate Gene Expression.

Lawrence, M., Daujat, S., & Schneider, R. (2016) · Trends in Genetics · doi:10.1016/j.tig.2015.10.007 · Cited by 759 · see citing works

The SWI/SNF complex in cancer — biology, biomarkers and therapy

Mittal, P., & Roberts, C. W. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0357-3 · Cited by 705 · see citing works

Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer

Fujimoto, A., Furuta, M., Totoki, Y., Tsunoda, T., Kato, M., Shiraishi, Y., Tanaka, H., Taniguchi, H., Kawakami, Y., Ueno, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3547 · Cited by 696 · see citing works

Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine

Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.016 · Cited by 659 · see citing works

Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells

Tsai, H.-C., Li, H., Neste, L. V., Cai, Y., Robert, C., Rassool, F. V., Shin, J., Harbom, K., Beaty, R. M., Pappou, E. P., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.029 · Cited by 651 · see citing works

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Italiano, A., Soria, J., Toulmonde, M., Michot, J., Lucchesi, C., Varga, A., Coindre, J., Blakemore, S. J., Clawson, A., Suttle, B. B., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30145-1 · Cited by 637 · see citing works

Advances in molecular classification and precision oncology in hepatocellular carcinoma

Rebouissou, S., & Nault, J. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.017 · Cited by 580 · see citing works

Epigenetic modifications of histones in cancer

Zhao, Z., & Shilatifard, A. (2019) · Genome biology · doi:10.1186/s13059-019-1870-5 · Cited by 561 · see citing works

Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma

Cheng, A., Hsu, C., Chan, S. L., Choo, S.-P., & Kudo, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.025 · Cited by 527 · see citing works

Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinomaPreprint

Kan, Z., Zheng, H., Liu, X., Li, S., Barber, T. D., Gong, Z., Gao, H., Hao, K., Willard, M. D., Xu, J., et al. (2013) · Genome Research · doi:10.1101/gr.154492.113 · Cited by 524 · see citing works

Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy

Lu, Y., Chan, Y.-T., Tan, H., Li, S., Wang, N., & Feng, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01197-3 · Cited by 506 · see citing works

Clinical epigenetics: seizing opportunities for translation

Berdasco, M., & Esteller, M. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0074-2 · Cited by 501 · see citing works

Understanding nucleosome dynamics and their links to gene expression and DNA replication

Lai, W. K. M., & Pugh, B. F. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.47 · Cited by 495 · see citing works

BET Proteins as Targets for Anticancer Treatment

Stathis, A., & Bertoni, F. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0605 · Cited by 463 · see citing works

Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise

Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 457 · see citing works

Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening

Sawey, E. T., Chanrion, M., Cai, C., Wu, G., Zhang, J., Zender, L., Zhao, A. S., Busuttil, R. W., Yee, H. T., Stein, L. D., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.040 · Cited by 437 · see citing works

The emerging role of epigenetic therapeutics in immuno-oncology

Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433 · see citing works

Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability

Milazzo, G., Mercatelli, D., Muzio, G. D., Triboli, L., Rosa, P. D., Perini, G., & Giorgi, F. M. (2020) · Genes · doi:10.3390/genes11050556 · Cited by 431 · see citing works

DNA methylation‐based prognosis and epidrivers in hepatocellular carcinoma

Villanueva, A., Portela, A., Sayols, S., Battiston, C., Hoshida, Y., Méndez‐González, J., Imbeaud, S., Letouzé, É., Hernández–Gea, V., Cornellà, H., et al. (2015) · Hepatology · doi:10.1002/hep.27732 · Cited by 430 · see citing works

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

Li, M., Zhao, H., Zhang, X., Wood, L. D., Anders, R. A., Choti, M. A., Pawlik, T. M., Daniel, H. D. J., Kannangai, R., Offerhaus, G. J. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.903 · Cited by 426 · see citing works

Genomic portrait of resectable hepatocellular carcinomas: Implications of <i>RB1</i> and <i>FGF19</i> aberrations for patient stratification

Ahn, S., Jang, S. J., Shim, J. H., Kim, D., Hong, S., Sung, C. O., Baek, D., Haq, F., Ansari, A. A., Lee, S. Y., et al. (2014) · Hepatology · doi:10.1002/hep.27198 · Cited by 424 · see citing works

Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy

Biswas, S., & Rao, C. M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.021 · Cited by 402 · see citing works

Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma

Calvisi, D. F., Ladu, S., Gorden, A., Farina, M., Lee, J., Conner, E. A., Schroeder, I. S., Factor, V. M., & Thorgeirsson, S. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31457 · Cited by 393 · see citing works

Epigenetic Changes Induced by Reactive Oxygen Species in Hepatocellular Carcinoma: Methylation of the E-cadherin Promoter

Lim, S., Gu, J.-M., Kim, M. S., Kim, H. S., Park, Y. N., Park, C. K., Cho, J. W., Park, Y. M., & Jung, G. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.027 · Cited by 378 · see citing works

The timeline of epigenetic drug discovery: from reality to dreams

Ganesan, A., Arimondo, P. B., Rots, M. G., Jerónimo, C., & Berdasco, M. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0776-0 · Cited by 342 · see citing works

Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma

Avila, M. A., Berasain, C., Torres, L., Martín‐Duce, A., Corrales, F. J., Yang, H., Prìeto, J., Lu, S. C.-L., Caballería, J., Rodés, J., et al. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80122-1 · Cited by 339 · see citing works

The future of epigenetic therapy in solid tumours—lessons from the past

Azad, N. S., Zahnow, C. A., Rudin, C. M., & Baylin, S. B. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.42 · Cited by 338 · see citing works

[Epidemiology of hepatocellular carcinoma].

Rosellini, S. R., & Miglio, F. (1992) · PubMed · Cited by 328 · see citing works

Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b

Kim, J. K., Noh, J. H., Jung, K. H., Eun, J. W., Bae, H. J., Kim, M. G., Chang, Y. G., Shen, Q., Park, W. S., Lee, J. Y., et al. (2012) · Hepatology · doi:10.1002/hep.26101 · Cited by 322 · see citing works

Aberrant Epigenetic Modifications in Hepatocarcinogenesis Induced by Hepatitis B Virus X Protein

Park, I. Y., Sohn, B. H., Yu, E., Suh, D. J., Chung, Y., Lee, J., SURZYCKI, S. J., & Lee, Y. I. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.034 · Cited by 320 · see citing works

Genetic profiling of hepatocellular carcinoma using next-generation sequencing

Schulze, K., Nault, J., & Villanueva, A. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.035 · Cited by 318 · see citing works

UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma

Mudbhary, R., Hoshida, Y., Chernyavskaya, Y., Jacob, V., Villanueva, A., Fiel, M. I., Chen, X., Kojima, K., Thung, S. N., Bronson, R. T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.003 · Cited by 310 · see citing works

Identification of driver genes in hepatocellular carcinoma by exome sequencing

Cleary, S. P., Jeck, W. R., Zhao, X., Chen, K., Selitsky, S. R., Savich, G. L., Tan, T. X., Wu, M. C., Getz, G. A., Lawrence, M. S., et al. (2013) · Hepatology · doi:10.1002/hep.26540 · Cited by 302 · see citing works

Marked for death: Targeting epigenetic changes in cancer

Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288 · see citing works

Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis

Au, S. L., Wong, C. C., Lee, J. M., Fan, D. N.-Y., Tsang, F. H., Ng, I. O., & Wong, C. (2012) · Hepatology · doi:10.1002/hep.25679 · Cited by 285 · see citing works

Expression of mRNA for DNA methyltransferases and methyl-CpG–binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis

Saito, Y. (2001) · Hepatology · doi:10.1053/jhep.2001.22507 · Cited by 265 · see citing works

Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas

Saito, Y., Kanai, Y., Nakagawa, T., Sakamoto, M., Saito, H., Ishii, H., & Hirohashi, S. (2003) · International Journal of Cancer · doi:10.1002/ijc.11127 · Cited by 259 · see citing works

Targeting Epigenetics in Cancer

Bennett, R. L., & Licht, J. D. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-105106 · Cited by 252 · see citing works

Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state

Kanai, Y., & Hirohashi, S. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm206 · Cited by 221 · see citing works

Hypermethylation of gene body CpG islands predicts high dosage of functional oncogenes in liver cancer

Arechederra, M., Daian, F., Yim, A., Bazai, S. K., Richelme, S., Dono, R., Saurin, A. J., Habermann, B. H., & Maina, F. (2018) · Nature Communications · doi:10.1038/s41467-018-05550-5 · Cited by 221 · see citing works

Genome-Wide Methylation Analysis and Epigenetic Unmasking Identify Tumor Suppressor Genes in Hepatocellular Carcinoma

Revill, K., Wang, T., Lachenmayer, A., Kojima, K., Harrington, A., Li, J., Hoshida, Y., Llovet, J. M., & Powers, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.055 · Cited by 217 · see citing works

5-Aza-2′-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation

Wozniak, R. J., Klimecki, W. T., Lau, S. S., Feinstein, Y., & Futscher, B. W. (2006) · Oncogene · doi:10.1038/sj.onc.1209763 · Cited by 213 · see citing works

SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3β/β-catenin signaling

Chen, J., Chan, A. W. H., To, K., Chen, W., Zhang, Z., Ren, J., Song, C., Cheung, Y. S., Lai, P. B. S., Cheng, S., et al. (2013) · Hepatology · doi:10.1002/hep.26278 · Cited by 213 · see citing works

BRD4 is a novel therapeutic target for liver fibrosis

Ding, N., Hah, N., Yu, R. T., Sherman, M. H., Benner, C., Leblanc, M., He, M., Liddle, C., Downes, M., & Evans, R. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522163112 · Cited by 211 · see citing works

EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Cheng, A. S. L., Lau, S. S., Chen, Y., Kondo, Y., Li, M. S. M., Feng, H., Ching, A. K.-K., Cheung, K. F., Wong, H. K., TONG, J. H. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3342 · Cited by 208 · see citing works

Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas

Ding, X., He, M., Chan, A. W. H., Song, Q. X., Sze, S. C., Chen, H., Man, K., Man, K., Chan, S. L., Lai, P. B. S., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.09.005 · Cited by 208 · see citing works

Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy

Dhanasekaran, R., Nault, J., Roberts, L. R., & Zucman‐Rossi, J. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.11.001 · Cited by 205 · see citing works

Methylation of DNA Ligase 1 by G9a/GLP Recruits UHRF1 to Replicating DNA and Regulates DNA Methylation

Ferry, L., Fournier, A., Tsusaka, T., Adelmant, G., Shimazu, T., Matano, S., Kirsh, O., Amouroux, R., Dohmae, N., Suzuki, T., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.07.012 · Cited by 203 · see citing works

Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression

Segovia, C., José‐Eneriz, E. S., Munera-Maravilla, E., Martínez‐Fernández, M., Gárate, L., Miranda, E., Vilas‐Zornoza, A., Lodewijk, I., Rubio, C., Segrelles, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0499-y · Cited by 188 · see citing works

Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review

Nishida, N., & Goel, A. (2011) · Current Genomics · doi:10.2174/138920211795564359 · Cited by 180 · see citing works

Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting

Avila, M., Dufour, J., Gerbes, A., Zoulim, F., Bataller, R., Burra, P., Cortez-Pinto, H., Gao, B., Gilmore, I., Mathurin, P., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-319720 · Cited by 179 · see citing works

Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

José‐Eneriz, E. S., Agirre, X., Rabal, O., Vilas‐Zornoza, A., Sánchez-Arias, J. A., Miranda, E., Ugarte, A., Roa, S., Paiva, B., de Mendoza, A. E., et al. (2017) · Nature Communications · doi:10.1038/ncomms15424 · Cited by 176 · see citing works

Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma

Liu, M., Zhou, J., Liu, X., Feng, Y., Yang, W., Wu, F., Cheung, O. K.-W., Sun, H., Zeng, X., Tang, W., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317257 · Cited by 175 · see citing works

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers

Diesch, J., Zwick, A., Garz, A.-K., Palau, A., Buschbeck, M., & Götze, K. S. S. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0237-y · Cited by 173 · see citing works

Greater Than the Sum of Parts: Complexity of the Dynamic Epigenome

Soshnev, A. A., Josefowicz, S. Z., & Allis, C. D. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.05.004 · Cited by 172 · see citing works

Targets for immunotherapy of liver cancer

Greten, T. F., & Sangro, B. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.007 · Cited by 170 · see citing works

Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3

Wei, L., Chiu, D. K., Tsang, F. H., Law, C., Cheng, C. L., Au, S. L., Lee, J. M., Wong, C. C., Wong, C., & Wong, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.015 · Cited by 167 · see citing works

Up‐regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis

Wong, C., Wei, L., Law, C., Ho, D. W., Tsang, F. H., Au, S. L., Sze, K. M., Lee, J. M., Wong, C. C., & Ng, I. O. (2015) · Hepatology · doi:10.1002/hep.28304 · Cited by 164 · see citing works

Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis

Um, T.-H., Kim, H., Oh, B.-K., Kim, M. S., Kim, K. S., Jung, G., & Park, Y. N. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.021 · Cited by 159 · see citing works

Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells

Bugide, S., Green, M. R., & Wajapeyee, N. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802691115 · Cited by 158 · see citing works

Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips

Shen, J., Wang, S., Zhang, Y., Wu, H., Kibriya, M. G., Jasmine, F., Ahsan, H., Wu, D., Siegel, A. B., Remotti, H. E., et al. (2012) · Epigenetics · doi:10.4161/epi.23062 · Cited by 157 · see citing works

Aberrant Super‐Enhancer Landscape in Human Hepatocellular Carcinoma

Tsang, F. H., Law, C., Tang, T. C. C., Cheng, C. L., Chin, D. W., Tam, V., Wei, L., Wong, C. C., Ng, I. O., & Wong, C. (2019) · Hepatology · doi:10.1002/hep.30544 · Cited by 153 · see citing works

Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma

Yarchoan, M. M., Agarwal, P., Villanueva, A., Rao, S., Dawson, L. A., Karasic, T. B., Llovet, J. M., Finn, R. S., Groopman, J. D., El‐Serag, H. B., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0803 · Cited by 153 · see citing works

Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma

Hirata, H., Sugimachi, K., Komatsu, H., Ueda, M., Masuda, T., Uchi, R., Sakimura, S., Nambara, S., Saito, T., Shinden, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2601 · Cited by 151 · see citing works

Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs

Brien, G. L., Valerio, D. G., & Armstrong, S. A. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.007 · Cited by 146 · see citing works

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study

Bitzer, M., Horger, M., Giannini, E. G., Ganten, T. M., Wörns, M., Siveke, J. T., Dollinger, M., Gerken, G., Scheulen, M. E., Wege, H., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.043 · Cited by 139 · see citing works

A Metabolic Roadmap for Somatic Stem Cell Fate

Ly, C., Lynch, G. S., & Ryall, J. G. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.022 · Cited by 138 · see citing works

Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma

Nishida, N., Kudo, M., Nagasaka, T., Ikai, I., & Goel, A. (2012) · Hepatology · doi:10.1002/hep.25706 · Cited by 137 · see citing works

Epigenetics and Liver Fibrosis

Morán‐Salvador, E., & Mann, J. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.04.007 · Cited by 137 · see citing works

Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model

Llópiz, D., Ruiz, M., Villanueva, L., Iglesias, T., Silva, L., Egea, J., Lasarte, J. J., Pivette, P., Trochon-Joseph, V., Vasseur, B., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2283-0 · Cited by 137 · see citing works

Histone Deacetylase HDAC8 Promotes Insulin Resistance and β-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma

Tian, Y., Wong, V. W., Wong, G. L., Yang, W., Sun, H., Shen, J., TONG, J. H. M., Go, M. Y. Y., Cheung, Y. S., Lai, P. B. S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3786 · Cited by 134 · see citing works

Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma

Huang, M., Chen, C. Y., Geng, J., Han, D. H., Wang, T., Xie, T., Wang, L., Wang, Y., Wang, C., Lei, Z., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.038 · Cited by 134 · see citing works

Vorinostat-An overview

Bubna, A. (2015) · Indian Journal of Dermatology · doi:10.4103/0019-5154.160511 · Cited by 131 · see citing works

Dual Targeting of Histone Methyltransferase G9a and DNA‐Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma

Bárcena‐Varela, M., Caruso, S., Llerena, S., Álvarez‐Sola, G., Uriarte, I., Latasa, M. U., Urtasun, R., Rebouissou, S., Alvarez, L., Jimenez, M., et al. (2019) · Hepatology · doi:10.1002/hep.30168 · Cited by 130 · see citing works

DNA Methylation Suppresses Expression of the Urea Cycle Enzyme Carbamoyl Phosphate Synthetase 1 (CPS1) in Human Hepatocellular Carcinoma

Liu, H., Dong, H., Robertson, K. D., & Liu, C. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.10.023 · Cited by 128 · see citing works

Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma

Gerbes, A. L., Zoulim, F., Tilg, H., Dufour, J., Bruix, J., Paradis, V., Salem, R., Peck‐Radosavljevic, M., Galle, P. R., Greten, T. F., et al. (2017) · Gut · doi:10.1136/gutjnl-2017-315068 · Cited by 127 · see citing works

Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review

Sawas, A., Radeski, D., & O’Connor, O. A. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715592567 · Cited by 121 · see citing works

Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice

Yuan, W., Lao, X., Xiao, C., Wang, X., Wu, Z.-J., Zeng, Q., Wu, C.-Y., Wu, R., Chen, Z.-X., Zheng, L., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.250 · Cited by 121 · see citing works

Epigenetics of hepatocellular carcinoma

Toh, T. B., Lim, J. J., & Chow, E. K. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0230-0 · Cited by 120 · see citing works

Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC

Quint, K., Agaimy, A., Fazio, P. D., Montalbano, R., Steindorf, C., Jung, R., Hellerbrand, C., Hartmann, A., Sitter, H., Neureiter, D., et al. (2011) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-011-1103-0 · Cited by 119 · see citing works

Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5+ liver cancer initiating cells by suppressing negative regulators of β-catenin signaling

Lei, Z.-J., Wang, J., Xiao, H.-L., Guo, Y., Wang, T., Li, Q., Liu, L., Luo, X., Fan, L.-L., Li, L., et al. (2015) · Oncogene · doi:10.1038/onc.2015.129 · Cited by 116 · see citing works

Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential

Tsui, Y., Chan, L., & Ng, I. O. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0823-9 · Cited by 115 · see citing works

Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers

Cheng, J., Wei, D., Ji, Y., Chen, L., Yang, L., Li, G., Wu, L., Hou, T., Xie, L., Ding, G., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0548-z · Cited by 114 · see citing works

Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells

Xiang, J., Zhang, N., Sun, H., Su, L., Zhang, C., Xu, H., Feng, J., Wang, M., Chen, J., Liu, L., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.10.025 · Cited by 113 · see citing works

Hepatitis Virus Infection Affects DNA Methylation in Mice With Humanized Livers

Okamoto, Y., Shinjo, K., Shimizu, Y., Sano, T., Yamao, K., Gao, W., Fujii, M., Osada, H., Sekido, Y., Murakami, S., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.056 · Cited by 113 · see citing works

Lysine Demethylase LSD1 Coordinates Glycolytic and Mitochondrial Metabolism in Hepatocellular Carcinoma Cells

Sakamoto, A., Hino, S., Nagaoka, K., Anan, K., Takase, R., Matsumori, H., Ojima, H., Kanai, Y., Arita, K., & Nakao, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1560 · Cited by 108 · see citing works

The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review

Rugo, H. S., Jacobs, I. A., Sharma, S., Scappaticci, F. A., Paul, T. A., Jensen-Pergakes, K., & Malouf, G. G. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01379-x · Cited by 108 · see citing works

Global DNA 5‐Hydroxymethylcytosine and 5‐Formylcytosine Contents Are Decreased in the Early Stage of Hepatocellular Carcinoma

Liu, J., Jiang, J., Mo, J., Liu, D., Cao, D., Wang, H., He, Y., & Wang, H. (2018) · Hepatology · doi:10.1002/hep.30146 · Cited by 107 · see citing works

A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets

Bayo, J., Fiore, E. J., Domínguez, L. M., Real, A., Malvicini, M., Rizzo, M., Atorrasagasti, C., García, M. G., Argemí, J., Martínez, E. D., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.007 · Cited by 107 · see citing works

Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming

Xiong, L., Wu, F., Wu, Q., Xu, L., Cheung, O. K.-W., Kang, W., Mok, M. T. S., Szeto, L. L. M., Lun, C.-Y., Lung, R. W. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08245-z · Cited by 105 · see citing works

Histone Lysine Methyltransferase, Suppressor of Variegation 3-9 Homolog 1, Promotes Hepatocellular Carcinoma Progression and Is Negatively Regulated by MicroRNA-125b

Fan, D. N.-Y., Tsang, F. H., Tam, A. H. K., Au, S. L., Wong, C. C., Wei, L., Lee, J. M., He, X., Ng, I. O., & Wong, C. (2012) · Hepatology · doi:10.1002/hep.26083 · Cited by 103 · see citing works

Integrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma

Hlady, R. A., Sathyanarayan, A., Thompson, J. J., Zhou, D., Wu, Q., Pham, K., Lee, J., Liu, C., & Robertson, K. D. (2019) · Hepatology · doi:10.1002/hep.30211 · Cited by 102 · see citing works

Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression

Yang, H. J., Jin, X., Yan, Y., Shao, Y., Pan, Y., Roberts, L. R., Zhang, J., Huang, H., & Jiang, J. (2017) · Scientific Reports · doi:10.1038/srep43864 · Cited by 100 · see citing works

Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma

Jühling, F., Hamdane, N., Crouchet, É., Shen, L., Saghire, H. E., Mukherji, A., Fujiwara, N., Oudot, M. A., Thumann, C., Saviano, A., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318918 · Cited by 98 · see citing works

Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis

Bárcena‐Varela, M., Paish, H. L., Alvarez, L., Uriarte, I., Latasa, M. U., Santamaría, E., Recalde, M., Garate, M., Clavería-Cabello, A., Colyn, L., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-320205 · Cited by 96 · see citing works

An Integrated Genomic and Epigenomic Approach Predicts Therapeutic Response to Zebularine in Human Liver Cancer

Andersen, J. B., Factor, V. M., Marquardt, J. U., Raggi, C., Lee, Y.-H., Seo, D., Conner, E. A., & Thorgeirsson, S. S. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001338 · Cited by 95 · see citing works

Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2

Lee, Y.-H., Seo, D., Choi, K., Andersen, J. B., Won, M.-A., Kitade, M., Gómez-Quiroz, L. E., Judge, A. D., Marquardt, J. U., Raggi, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3531 · Cited by 93 · see citing works

HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population

LER, S. Y., Leung, C. H., Khin, L. W., Lu, G., Salto‐Tellez, M., Hartman, M., Iau, P. T. C., Yap, C. T., & Hooi, S. C. (2015) · Oncology Reports · doi:10.3892/or.2015.4263 · Cited by 92 · see citing works

Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma

Liu, J., Liu, Y., Meng, L., Liu, K., & Ji, B. (2017) · Oncology Reports · doi:10.3892/or.2017.5722 · Cited by 91 · see citing works

Aberrant JMJD3 Expression Upregulates Slug to Promote Migration, Invasion, and Stem Cell–Like Behaviors in Hepatocellular Carcinoma

Tang, B., Qi, G., Tang, F., Yuan, S., Wang, Z., Liang, X., Li, B., Yu, S., Liu, J., Huang, Q., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3029 · Cited by 89 · see citing works

Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis

Hlady, R. A., Tiedemann, R. L., Puszyk, W. M., Zendejas, I. R., Roberts, L. R., Choi, J.-H., Liu, C., & Robertson, K. D. (2014) · Oncotarget · doi:10.18632/oncotarget.2444 · Cited by 88 · see citing works

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma

Jueliger, S., Lyons, J. F., Cannito, S., Pata, I., Pata, P., Školnaja, M., Re, O. L., Peyrou, M., Villarroya, F., Pazienza, V., et al. (2016) · Epigenetics · doi:10.1080/15592294.2016.1214781 · Cited by 87 · see citing works

LncRNAs as Chromatin Regulators in Cancer: From Molecular Function to Clinical Potential

Begolli, R., Sideris, N., & Giakountis, A. (2019) · Cancers · doi:10.3390/cancers11101524 · Cited by 84 · see citing works

Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients

Zhao, Z.-K. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i45.6651 · Cited by 83 · see citing works

Role of the Hypoxia-Related Gene, JMJD1A, in Hepatocellular Carcinoma: Clinical Impact on Recurrence after Hepatic Resection

Yamada, D., Kobayashi, S., Yamamoto, H., Tomimaru, Y., Noda, T., Uemura, M., Wada, H., Marubashi, S., Eguchi, H., Tanemura, M., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1797-x · Cited by 83 · see citing works

ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation

Lin, Q., Wu, Z., Yue, X., Yu, X., Wang, Z., Song, X., Xu, L., He, Y., Ge, Y., Tan, S., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102676 · Cited by 81 · see citing works

Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells

Gailhouste, L., Liew, L. C., Yasukawa, K., Hatada, I., Tanaka, Y., Nakagama, H., & Ochiya, T. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.018 · Cited by 77 · see citing works

Development and validation of a CIMP-associated prognostic model for hepatocellular carcinoma

Li, G., Xu, W., Zhang, L., Liu, T., Jin, G.-N., Song, J., Wu, J., Wang, Y., Chen, W., Zhang, C., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.064 · Cited by 76 · see citing works

A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients

Feng, H., Yu, Z., Tian, Y., Lee, Y., Li, M. S. M., Go, M. Y. Y., Cheung, Y. S., Lai, P. B. S., Chan, A. M.-L., To, K., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.040 · Cited by 75 · see citing works

Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma

Hong, Y. K., Li, Y., Pandit, H., Li, S., Pulliam, Z., Zheng, Q., Yu, Y., & Martin, R. C. G. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2018.12.010 · Cited by 74 · see citing works

Molecular Processes Connecting DNA Methylation Patterns with DNA Methyltransferases and Histone Modifications in Mammalian Genomes

Jeltsch, A., Broche, J., & Bashtrykov, P. (2018) · Genes · doi:10.3390/genes9110566 · Cited by 74 · see citing works

Genome-wide DNA methylation analysis during non-alcoholic steatohepatitis-related multistage hepatocarcinogenesis: comparison with hepatitis virus-related carcinogenesis

Kuramoto, J., Arai, E., Tian, Y., Funahashi, N., Hiramoto, M., Nammo, T., Nozaki, Y., Takahashi, Y., Ito, N., Shibuya, A., et al. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx005 · Cited by 72 · see citing works

Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis

Bárcena‐Varela, M., Colyn, L., & Fernández‐Barrena, M. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102507 · Cited by 71 · see citing works

Symphony of epigenetic and metabolic regulation—interaction between the histone methyltransferase EZH2 and metabolism of tumor

Zhang, T., Gong, Y., Meng, H., Li, C., & Xue, L. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00862-0 · Cited by 71 · see citing works

MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET–SOCS1–MMP9 signaling axis

Chen, Q., Yin, D., Zhang, Y., Yu, L., Li, X., Zhou, Z., Zhou, S., Gao, D., Hu, J., Jin, C. S., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.142 · Cited by 71 · see citing works

Hepatocyte growth factor induces MAT2A expression and histone acetylation in rat hepatocytes: role in liver regeneration 1

Latasa, M. U., Boukaba, A., García–Trevijano, E. R., Torres, L., Rodrı́guez, J. L., Caballería, J., Lu, S. C.-L., López‐Rodas, G., Franco, L., Mato, J. M., et al. (2001) · The FASEB Journal · doi:10.1096/fj.00-0556fjev1 · Cited by 65 · see citing works

Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI‐110) in Hepatocellular Carcinoma

Liu, M., Zhang, L., Li, H., Hinoue, T., Zhou, W., Ohtani, H., El-Khoueiry, A. B., Daniels, J. R., O'Connell, C. L., Dorff, T. B., et al. (2018) · Hepatology · doi:10.1002/hep.30091 · Cited by 65 · see citing works

Targeting Chromatin Remodeling for Cancer Therapy

Kaur, J., Daoud, A., & Eblen, S. T. (2019) · Current Molecular Pharmacology · doi:10.2174/1874467212666190215112915 · Cited by 65 · see citing works

Global DNA methylation and hydroxymethylation differ in hepatocellular carcinoma and cholangiocarcinoma and relate to survival rate

Udali, S., Guarini, P., Moruzzi, S., Ruzzenente, A., Tammen, S. A., Guglielmi, A., Conci, S., Pattini, P., Olivieri, O., Corrocher, R., et al. (2015) · Hepatology · doi:10.1002/hep.27823 · Cited by 64 · see citing works

BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma

Zhang, P., Dong, Z., Cai, J., Zhang, C., Shen, Z., Ke, A., Gao, D., Fan, J., & Shi, G. (2015) · International Journal of Immunopathology and Pharmacology · doi:10.1177/0394632015572070 · Cited by 63 · see citing works

Gene-Specific Actions of Transcriptional Coregulators Facilitate Physiological Plasticity: Evidence for a Physiological Coregulator Code

Stallcup, M. R., & Poulard, C. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.02.006 · Cited by 63 · see citing works

Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma

Choy, E., Flamand, Y., Balasubramanian, S., Butrynski, J. E., Harmon, D. C., George, S., Cote, G. M., Wagner, A. J., Morgan, J. A., Sirisawad, M., et al. (2014) · Cancer · doi:10.1002/cncr.29175 · Cited by 62 · see citing works

Epigenetic landscape influences the liver cancer genome architecture

Hama, N., Totoki, Y., Miura, F., Tatsuno, K., Saito-Adachi, M., Nakamura, H., Arai, Y., Hosoda, F., Urushidate, T., Ohashi, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03999-y · Cited by 60 · see citing works

Guadecitabine (SGI‐110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin

Kuang, Y., El-Khoueiry, A. B., Taverna, P., Ljungman, M. E., & Neamati, N. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.06.002 · Cited by 57 · see citing works

Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer

Menon, D. R., Hammerlindl, H., Torrano, J., Schaider, H., & Fujita, M. (2020) · Theranostics · doi:10.7150/thno.42523 · Cited by 57 · see citing works

A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets

Wijetunga, N. A., Pascual, M., Tozour, J. N., Delahaye, F., Alani, M. T., Adeyeye, M., Wolkoff, A. W., Verma, A. K., & Greally, J. M. (2016) · Oncogene · doi:10.1038/onc.2016.340 · Cited by 55 · see citing works

Towards a more precise therapy in cancer: Exploring epigenetic complexity

Cossío, F. P., Esteller, M., & Berdasco, M. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.04.008 · Cited by 55 · see citing works

Mechanisms of DNA Methyltransferase Recruitment in Mammals

Laisné, M., Gupta, N., Kirsh, O., Pradhan, S., & Defossez, P. (2018) · Genes · doi:10.3390/genes9120617 · Cited by 50 · see citing works

An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma

Mei, Q., Chen, M., Lu, X.-C., Li, X., Duan, F., Wang, M., Luo, G., & Han, W. (2015) · Oncotarget · doi:10.18632/oncotarget.3677 · Cited by 50 · see citing works

Protein Interactions at Oxidized 5-Methylcytosine Bases

Pfeifer, G. P., Szabó, P. E., & Song, J. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.07.039 · Cited by 49 · see citing works

MeCP2 and Chromatin Compartmentalization

Schmidt, A., Zhang, H., & Cardoso, M. C. (2020) · Cells · doi:10.3390/cells9040878 · Cited by 48 · see citing works

Metabolic reprogram associated with epithelial-mesenchymal transition in tumor progression and metastasis

Wang, Y., Dong, C., & Zhou, B. P. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.09.012 · Cited by 47 · see citing works

Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage

Nagashio, R., Arai, E., Ojima, H., Kosuge, T., Kondo, Y., & Kanai, Y. (2011) · International Journal of Cancer · doi:10.1002/ijc.26061 · Cited by 44 · see citing works

Models for Understanding Resistance to Chemotherapy in Liver Cancer

Marı́n, J. J. G., Herráez, E., Lozano, E., Macı́as, R. I. R., & Briz, Ó. (2019) · Cancers · doi:10.3390/cancers11111677 · Cited by 43 · see citing works

Reading Cancer: Chromatin Readers as Druggable Targets for Cancer Treatment

Mio, C., Bulotta, S., Russo, D., & Damante, G. (2019) · Cancers · doi:10.3390/cancers11010061 · Cited by 43 · see citing works

Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma

Shigekawa, Y., Hayami, S., Ueno, M., Miyamoto, A., Suzaki, N., Kawai, M., Hirono, S., Okada, K., Hamamoto, R., & Yamaue, H. (2018) · Oncotarget · doi:10.18632/oncotarget.26144 · Cited by 40 · see citing works

Role of ten‐eleven translocation proteins and 5‐hydroxymethylcytosine in hepatocellular carcinoma

Wang, P., Yan, Y., Yu, W., & Zhang, H. (2019) · Cell Proliferation · doi:10.1111/cpr.12626 · Cited by 40 · see citing works

The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review

Hu, B., Lin, J., Yang, X., & Sang, X. (2020) · Cell Proliferation · doi:10.1111/cpr.12791 · Cited by 40 · see citing works

Episensitization: Defying Time’s Arrow

Oronsky, B. T., Oronsky, A. L., Lybeck, M., Oronsky, N. C., Scicinski, J. J., Carter, C. A., Day, R. M., Rodríguez‐Orengo, J. F., Rodriguez‐Torres, M., Fanger, G. R., et al. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00134 · Cited by 37 · see citing works

Unraveling the Epigenetic Basis of Liver Development, Regeneration and Disease

Macchi, F., & Sadler, K. C. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.05.002 · Cited by 37 · see citing works

The histone acetyltransferase hMOF promotes vascular invasion in hepatocellular carcinoma

Poté, N., Cros, J. F., Laouirem, S., Raffenne, J., Negrão, M., Albuquerque, M., Bédossa, P., Ferreira, M. G., Ait‐Si‐Ali, S., Fior, R., et al. (2020) · Liver International · doi:10.1111/liv.14381 · Cited by 35 · see citing works

Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer

Zhao, J., Gray, S. G., Greene, C. M., & Lawless, M. W. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1568870 · Cited by 33 · see citing works

Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis

Soukupová, J., Bertrán, E., Peñuelas‐Haro, I., Urdiroz-Urricelqui, U., Borgman, M., Kohlhof, H., & Fabregat, I. (2017) · Oncotarget · doi:10.18632/oncotarget.22775 · Cited by 33 · see citing works

Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting

Reddy, S. A. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.07.001 · Cited by 31 · see citing works

Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis

Kim, H. S., Shen, Q., & Nam, S. W. (2015) · Journal of Korean Medical Science · doi:10.3346/jkms.2015.30.10.1375 · Cited by 29 · see citing works

Chromatin dynamics during liver regeneration

Arechederra, M., Berasain, C., Avila, M. A., & Fernández-Barrena, M. G. (2020) · Seminars in Cell &amp; Developmental Biology · doi:10.1016/j.semcdb.2019.03.004 · Cited by 28 · see citing works

Epigenetic dysregulation in hepatocellular carcinoma: focus on polycomb group proteins

Au, S. L., Ng, I. O., & Wong, C. (2013) · Frontiers of Medicine · doi:10.1007/s11684-013-0253-7 · Cited by 26 · see citing works

Signaling coupled epigenomic regulation of gene expression

Kumar, R., Sankaran, D., Santhoshkumar, T. R., & Pillai, M. R. (2017) · Oncogene · doi:10.1038/onc.2017.201 · Cited by 25 · see citing works

Reading between the Lines: “ADD”-ing Histone and DNA Methylation Marks toward a New Epigenetic “Sum”

Noh, K., Allis, C. D., & Li, H. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00830 · Cited by 24 · see citing works

Small Molecules Targeting the Specific Domains of Histone-Mark Readers in Cancer Therapy

Zhu, H., Wei, T., Cai, Y., & Jin, J. (2020) · Molecules · doi:10.3390/molecules25030578 · Cited by 22 · see citing works

JMJD2B as a potential diagnostic immunohistochemical marker for hepatocellular carcinoma: A tissue microarray-based study

Lu, J., Ho, Y., Lin, L., Huang, Y.-C., Yeh, K.-T., Lin, Y.-H., Lin, Y.-M., & Tzeng, T. (2014) · Acta Histochemica · doi:10.1016/j.acthis.2014.10.002 · Cited by 20 · see citing works

Non-Coding RNAs: Regulating Disease Progression and Therapy Resistance in Hepatocellular Carcinoma

Manna, D., & Sarkar, D. (2020) · Cancers · doi:10.3390/cancers12051243 · Cited by 19 · see citing works

Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature

Grecea, M., Marabelle, A., Ammari, S., Massard, C., & Champiat, S. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0671 · Cited by 18 · see citing works

Prognostic and clinicopathologic significance of SIRT1 expression in hepatocellular carcinoma

Jiang, H., Zhang, X., Tao, Y., Liang, S., Jiang, Q., Yu, Y., Cai, F., & Ma, L. (2016) · Oncotarget · doi:10.18632/oncotarget.14096 · Cited by 18 · see citing works

Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat

Cavenagh, J. D., & Popat, R. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.05.007 · Cited by 18 · see citing works

Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers

Wang, Y., & Deng, B. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10084-4 · Cited by 434 · see citing works

Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections

Martínez, M. G., Boyd, A. C., Combe, E., Testoni, B., & Zoulim, F. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.013 · Cited by 166 · see citing works

Epigenetics in NAFLD/NASH: Targets and therapy

Sodum, N., Kumar, G., Bojja, S. L., Kumar, N., & Rao, C. M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105484 · Cited by 145 · see citing works

ALKBH5/MAP3K8 axis regulates PD-L1+ macrophage infiltration and promotes hepatocellular carcinoma progression

You, Y., Wen, D., Zeng, L., Lu, J., Xiao, X., Chen, Y., Song, H., & Liu, Z. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70149 · Cited by 135 · see citing works

Epigenetic remodelling in human hepatocellular carcinoma

Braghini, M. R., Re, O. L., Romito, I., Fernández‐Barrena, M. G., Barbaro, B., Pomella, S., Rota, R., Vinciguerra, M., Avila, M. A., & Alisi, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02297-2 · Cited by 88 · see citing works

Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy

Liu, Q., Guan, Y., & Li, S. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02095-8 · Cited by 83 · see citing works

Diagnostic Significance of hsa-miR-21-5p, hsa-miR-192-5p, hsa-miR-155-5p, hsa-miR-199a-5p Panel and Ratios in Hepatocellular Carcinoma on Top of Liver Cirrhosis in HCV-Infected Patients

Eldosoky, M. A. E. R., Hammad, R., Elmadbouly, A. A. E., Aglan, R. B., AbdelHamid, S. G., Alboraie, M. A. A., Hassan, D. A., Shaheen, M. A. A., Rushdi, A., Ahmed, R. M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043157 · Cited by 73 · see citing works

Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making

Dhanasekaran, R., Suzuki, H., Lemaitre, L., Kubota, N., & Hoshida, Y. (2023) · Hepatology · doi:10.1097/hep.0000000000000513 · Cited by 69 · see citing works

Epigenetic regulation in macrophage migration inhibitory factor (MIF)-mediated signaling in cancer and inflammation

Osipyan, A., Chen, D., & Dekker, F. J. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.03.012 · Cited by 59 · see citing works

Novel Therapies for the Treatment of Cardiac Fibrosis Following Myocardial Infarction

Raziyeva, K., Kim, Y., Zharkinbekov, Z., Temirkhanova, K., & Saparov, A. (2022) · Biomedicines · doi:10.3390/biomedicines10092178 · Cited by 56 · see citing works

Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

Clavería-Cabello, A., Herranz, J. M., Latasa, M. U., Arechederra, M., Uriarte, I., Pineda‐Lucena, A., Prósper, F., Berraondo, P., Alonso, C., Sangro, B., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.031 · Cited by 55 · see citing works

Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease

Arechederra, M., Recalde, M., Gárate‐Rascón, M., Fernández‐Barrena, M. G., Avila, M. A., & Berasain, C. (2021) · Cancers · doi:10.3390/cancers13061265 · Cited by 53 · see citing works

The Endless Sources of Hepatocellular Carcinoma Heterogeneity

Bárcena-Varela, M., & Lujambio, A. (2021) · Cancers · doi:10.3390/cancers13112621 · Cited by 41 · see citing works

Epigenetics of alcohol-related liver diseases

Habash, N. W., Sehrawat, T. S., Shah, V. H., & Cao, S. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100466 · Cited by 41 · see citing works

Hepatitis B virus X protein mediated epigenetic alterations in the pathogenesis of hepatocellular carcinoma

Yang, L., Zou, T., Chen, Y., Zhao, Y., Wu, X., Li, M., Du, F., Chen, Y., Xiao, Z., & Shen, J. (2022) · Hepatology International · doi:10.1007/s12072-022-10351-6 · Cited by 39 · see citing works

TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway

Dong, R., Wang, T., Dong, W., Zhang, H., Li, Y., Tao, R., Liu, Q., Liang, H., Chen, X., Zhang, B., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.038 · Cited by 38 · see citing works

Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment

Martínez‐Chantar, M. L., Avila, M. A., & Lu, S. C.-L. (2020) · Cancers · doi:10.3390/cancers12102729 · Cited by 37 · see citing works

HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma

Shen, C., Li, M., Duan, Y., Jiang, X., Hou, X., Xue, F., Zhang, Y., & Luo, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1170207 · Cited by 36 · see citing works

Deregulated bile acids may drive hepatocellular carcinoma metastasis by inducing an immunosuppressive microenvironment

Xia, J., Tang, N., Wu, X., & Ren, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1033145 · Cited by 32 · see citing works

How CLSPN could demystify its prognostic value and potential molecular mechanism for hepatocellular carcinoma: A crosstalk study

Shi, Y., Wang, Y., Niu, K., Zhang, W., Lv, Q., & Zhang, Y. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108260 · Cited by 32 · see citing works

The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective

Unfried, J. P., Sangro, P., Prats-Mari, L., Sangro, B., & Fortes, P. (2021) · Cancers · doi:10.3390/cancers13112651 · Cited by 31 · see citing works

Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects

Romito, I., Porru, M., Braghini, M. R., Pompili, L., Panera, N., Crudele, A., Gnani, D., Stefanis, C. D., Scarsella, M., Pomella, S., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02154-8 · Cited by 30 · see citing works

Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma

Zeisel, M. B., Guerrieri, F., & Levrero, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081715 · Cited by 29 · see citing works

Role of the Epigenetic Modifier JMJD6 in Tumor Development and Regulation of Immune Response

Wang, K., Yang, C., Li, H., Liu, X., Zheng, M., Xuan, Z., Mei, Z., & Wang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859893 · Cited by 30 · see citing works

Epigenetic mechanisms involved in hepatocellular carcinoma development and progression

Bueloni, B., Fernández‐Barrena, M. G., Avila, M. A., Bayo, J., & Mazzolini, G. D. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100186 · Cited by 30 · see citing works

Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma

Basu, A., Namporn, T., & Ruenraroengsak, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061611 · Cited by 27 · see citing works

Inhibition of histone demethylase KDM4 by ML324 induces apoptosis through the unfolded protein response and Bim upregulation in hepatocellular carcinoma cells

Kim, S. Y., Hwang, S., Lee, B., Hong, J. A., Sung, Y. H., & Kim, I. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.109806 · Cited by 25 · see citing works

Molecular Mechanisms in Tumorigenesis of Hepatocellular Carcinoma and in Target Treatments—An Overview

Szilveszter, R.-M., Muntean, M., & Florea, A. (2024) · Biomolecules · doi:10.3390/biom14060656 · Cited by 26 · see citing works

SMYD5 is a ribosomal methyltransferase that catalyzes RPL40 lysine methylation to enhance translation output and promote hepatocellular carcinoma

Miao, B., Ge, L., He, C., Wang, X., Wu, J., Li, X., Chen, K., Wan, J., Xing, S., Ren, L., et al. (2024) · Cell Research · doi:10.1038/s41422-024-01013-3 · Cited by 23 · see citing works

The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active

Sequera, C., Grattarola, M., Cannet, F., Dobric, A., Veloso, P. M., Methia, M., Richelme, S., Kaoutari, A. E., Kousteridou, P., Debayle, D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62934-0 · Cited by 23 · see citing works

Circulating Tumor DNA Methylation Biomarkers for Characterization and Determination of the Cancer Origin in Malignant Liver Tumors

Draškovič, T., Zidar, N., & Hauptman, N. (2023) · Cancers · doi:10.3390/cancers15030859 · Cited by 22 · see citing works

Epigenetic regulation and its therapeutic potential in hepatitis B virus covalently closed circular DNA

Ren, J., Cheng, S., Ren, F., Gu, H., Wu, D., Yao, X., Tan, M., Huang, A., & Chen, J. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101215 · Cited by 21 · see citing works

5-Azacytidine Downregulates the Proliferation and Migration of Hepatocellular Carcinoma Cells In Vitro and In Vivo by Targeting miR-139-5p/ROCK2 Pathway

Tonon, F., Čemažar, M., Kamenšek, U., Zennaro, C., Pozzato, G., Caserta, S., Ascione, F., Grassi, M., Guido, S., Ferrari, C., et al. (2022) · Cancers · doi:10.3390/cancers14071630 · Cited by 21 · see citing works

The Epigenetic Regulation of Microenvironment in Hepatocellular Carcinoma

Wang, F., Malnassy, G., & Qiu, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.653037 · Cited by 19 · see citing works

Comprehensive analysis of epigenetic and epitranscriptomic genes’ expression in human NAFLD

Herranz, J. M., López-Pascual, A., Clavería-Cabello, A., Uriarte, I., Latasa, M. U., Irigaray-Miramon, A., Adán-Villaescusa, E., Castelló-Uribe, B., Sangro, B., Arechederra, M., et al. (2023) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-023-00976-y · Cited by 21 · see citing works

DNA methylation in cell plasticity and malignant transformation in liver diseases

Kim, M., Delgado, E. R., & Ko, S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108334 · Cited by 20 · see citing works

Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis

Bi, L., Wang, X., Li, J., Li, W., & Wang, Z. (2025) · MedComm · doi:10.1002/mco2.70080 · Cited by 18 · see citing works

MiRNAs in Alcohol-Related Liver Diseases and Hepatocellular Carcinoma: A Step toward New Therapeutic Approaches?

Jouve, M., Carpentier, R., Kraiem, S., Legrand, N., & Sobolewski, C. (2023) · Cancers · doi:10.3390/cancers15235557 · Cited by 18 · see citing works

Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights

Rahdan, F., Saberi, A., Saraygord‐Afshari, N., Hadizadeh, M., Arjmand, T. F., Ghanbari, E., Dianat‐Moghadam, H., & Alizadeh, E. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39489 · Cited by 18 · see citing works

Integration of epigenomic and transcriptomic profiling uncovers EZH2 target genes linked to cysteine metabolism in hepatocellular carcinoma

Lee, J., You, C., Kwon, G., Noh, J., Lee, K., Kim, K., Kang, K., & Kang, K. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07198-0 · Cited by 17 · see citing works

Methylated circulating tumor DNA in hepatocellular carcinoma: A comprehensive analysis of biomarker potential and clinical implications

Zhu, Q., Xie, J., Mei, W., & Zeng, C. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102763 · Cited by 16 · see citing works

DNA Methylation of TGFβ Target Genes: Epigenetic Control of TGFβ Functional Duality in Liver Cancer

Bévant, K., Desoteux, M., Wahab, A. H. A. A., Abdel-Wahab, S., Metwally, A. M., & Coulouarn, C. (2021) · Cells · doi:10.3390/cells10092207 · Cited by 16 · see citing works

Identification of NAA40 as a Potential Prognostic Marker for Aggressive Liver Cancer Subtypes

Koufaris, C., & Kirmizis, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.691950 · Cited by 15 · see citing works

Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics

Wang, H., Chen, X., & Calvisi, D. F. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1976142 · Cited by 15 · see citing works

Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7

Chen, J., Zhao, Y., Zhang, F., Li, J., Boland, J. A., Cheng, N. C., Liu, K., Tiffen, J. C., Bertolino, P., Bowen, D. G., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04452-6 · Cited by 14 · see citing works

Hydroxymethylbilane synthase (aka porphobilinogen deaminase): A novel metabolic tumor suppressor gene in hepatocellular carcinoma

Fontanellas, A., & Avila, M. A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.023 · Cited by 14 · see citing works

Emerging roles of interactions between ncRNAs and other epigenetic modifications in breast cancer

Xie, J., Gan, L., Xue, B., Wang, X., & Pei, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1264090 · Cited by 13 · see citing works

Differential methylation patterns in lean and obese non-alcoholic steatohepatitis-associated hepatocellular carcinoma

Hymel, E., Fisher, K. W., & Farazi, P. A. (2022) · BMC Cancer · doi:10.1186/s12885-022-10389-7 · Cited by 13 · see citing works

Epigenetic mechanisms in HCC immune landscape: Therapeutic implications

Fernández‐Barrena, M. G., Uriarte, I., Sarobe, P., & Avila, M. A. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.101980 · Cited by 14 · see citing works

The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation

Recalde, M., Gárate‐Rascón, M., Elizalde, M., Azkona, M., Latasa, M. U., Bárcena‐Varela, M., Sangro, B., Fernández‐Barrena, M. G., Avila, M. A., Arechederra, M., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab649 · Cited by 11 · see citing works

E2F1 as a potential prognostic and therapeutic biomarker by affecting tumor development and immune microenvironment in hepatocellular carcinoma

Tan, Z., Chen, M., Peng, F., Yang, P., Peng, Z., Zhang, Z., Li, X., Zhu, X., Zhang, L., Zhao, Y., et al. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-218 · Cited by 12 · see citing works

Decitabine-based nanoparticles for enhanced immunotherapy of hepatocellular carcinoma via DNA hypermethylation reversal

Cai, H., Li, X., Liu, Y., Ke, J., Liu, K., Xie, Y., Xie, C., Zhou, D., Han, M., & Ji, B. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.152175 · Cited by 12 · see citing works

Expression landscape of epigenetic genes in human hepatocellular carcinoma

Castelló-Uribe, B., López-Pascual, A., Elurbide, J., Adán-Villaescusa, E., Valbuena-Goiricelaya, E., Martínez‐Pérez, L. A., Uriarte, I., Latasa, M. U., Sangro, B., Arechederra, M., et al. (2025) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-025-01095-6 · Cited by 11 · see citing works

SUV39H1 is a novel biomarker targeting oxidative phosphorylation in hepatitis B virus-associated hepatocellular carcinoma

Zhang, Y., Lao, W., Yang, K., Kong, X., Li, Y., Yu, X., Wang, X., Liu, Y., Li, Z., Deng, Y., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11633-4 · Cited by 11 · see citing works

DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis

Recalde, M., Gárate-Rascón, M., Herranz, J. M., Elizalde, M., Azkona, M., Unfried, J. P., Boix, L., Reig, M., Sangro, B., Fernández-Barrena, M. G., et al. (2022) · Cancers · doi:10.3390/cancers14092048 · Cited by 14 · see citing works

Normalization of the ATP1A1 Signalosome Rescinds Epigenetic Modifications and Induces Cell Autophagy in Hepatocellular Carcinoma

Rajan, P. K., Udoh, U. S., Nakafuku, Y., Pierre, S. V., & Sanabria, J. R. (2023) · Cells · doi:10.3390/cells12192367 · Cited by 10 · see citing works

H4K20me3 upregulated by reactive oxygen species is associated with tumor progression and poor prognosis in patients with hepatocellular carcinoma

Phoyen, S., Sanpavat, A., Ma-on, C., Stein, U., Hirankarn, N., Tangkijvanich, P., Jindatip, D., Whongsiri, P., & Boonla, C. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22589 · Cited by 10 · see citing works

The Loss of an Orphan Nuclear Receptor NR2E3 Augments Wnt/β‐catenin Signaling via Epigenetic Dysregulation that Enhances Sp1‐β catenin‐p300 Interactions in Hepatocellular Carcinoma

Leung, Y., Lee, S., Wang, J., Guruvaiya, P., Rusch, N. J., Ho, S., Park, C., & Kim, K. (2024) · Advanced Science · doi:10.1002/advs.202308539 · Cited by 10 · see citing works

SPATS2 is positively activated by long noncoding RNA SNHG5 via regulating DNMT3a expression to promote hepatocellular carcinoma progression

Yan, J., Huang, Q. Y., Huang, Y. J., Wang, C. S., & Liu, P. X. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262262 · Cited by 10 · see citing works

TACE inhibition: a promising therapeutic intervention against AATF ‐mediated steatohepatitis to hepatocarcinogenesis

Srinivas, A. N., Suresh, D., Vishwanath, P. M., Satish, S., Santhekadur, P. K., Koka, S., & Kumar, D. P. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13646 · Cited by 8 · see citing works

Pirfenidone Reverts Global DNA Hypomethylation, Promoting DNMT1/UHRF/PCNA Coupling Complex in Experimental Hepatocarcinoma

Miranda-Roblero, H. O., Saavedra-Salazar, L. F., Galicia‐Moreno, M., Arceo-Orozco, S., Caloca-Camarena, F., Sandoval-Rodriguez, A. S., Garcia-Bañuelos, J. J., Frias-Gonzalez, C., Almeida-López, M., Martínez‐López, E., et al. (2024) · Cells · doi:10.3390/cells13121013 · Cited by 8 · see citing works

Epigenetic Modifications in HBV ‐Related Hepatocellular Carcinoma

Tan, X., Xun, L., Yin, Q., Chen, C., Zhang, T., & Shen, T. (2025) · Journal of Viral Hepatitis · doi:10.1111/jvh.14044 · Cited by 7 · see citing works

Zingiberensis Newsaponin Inhibits the Malignant Progression of Hepatocellular Carcinoma via Suppressing Autophagy Moderated by the AKR1C1-Mediated JAK2/STAT3 Pathway

He, K., Liu, X., Cheng, S., & Zhou, P. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/4055209 · Cited by 8 · see citing works

Computer analysis of regulation of hepatocarcinoma marker genes hypermethylated by HCV proteins

Antropova, E. A., Khlebodarova, T. M., Сергеевич, Д. П., Сергеевич, В. А., Ivanisenko, N. V., Gavrilenko, A. D., Ivanisenko, T., Adamovskaya, A. V., Revva, P. M., Lavrik, I. N., et al. (2023) · Vavilov Journal of Genetics and Breeding · doi:10.18699/vjgb-22-89 · Cited by 8 · see citing works

Genetic screening of liver cancer: State of the art

Peruhova, M., Banova-Chakarova, S., Miteva, D., & Velikova, T. V. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.716 · Cited by 7 · see citing works

Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications

Bueloni, B., Fernández‐Barrena, M. G., Fiore, E. J., Avila, M. A., Bayo, J., & Mazzolini, G. D. (2025) · Gut · doi:10.1136/gutjnl-2025-336317 · Cited by 7 · see citing works

SMARCA4 (BRG1) activates ABCC3 transcription to promote hepatocellular carcinogenesis

Liu, H., Yue, L., Hong, W., & Zhou, J. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122605 · Cited by 6 · see citing works

The hepatoprotective effect of sodium butyrate on hepatic inflammatory injury mediated by the NLRP3 inflammatory pathway in subchronic fluoride-exposed mice

Li, W., Ma, Z., Su, C., Liu, F., Yan, N., Duan, X., Sun, Z., Wang, H., Ma, Y., Wang, Z., et al. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09926-3 · Cited by 6 · see citing works

Mitoepigenetics pathways and natural compounds: a dual approach to combatting hepatocellular carcinoma

Hatawsh, A., Al-Haddad, R. H., Okafor, U. G., Diab, L. M., Dekanoidze, N., Abdulwahab, A. A., Mohammed, O. A., Doghish, A. S., Moussa, R., & Elimam, H. (2024) · Medical Oncology · doi:10.1007/s12032-024-02538-8 · Cited by 6 · see citing works

Heterocyclic compounds in targeted treatment of hepatocellular Carcinoma: Mechanistic Insights and clinical Implications

Kaur, K., Jain, P., Chelike, D. K., & Ajazuddin, M. (2025) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2025.114704 · Cited by 6 · see citing works

Impact of CYLD on chromatin structure and histone methylation in malignant melanoma

Schott, M., Kappelmann‐Fenzl, M., Fischer, S., Fernández‐Barrena, M. G., Pineda‐Lucena, A., Avila, M. A., Kuphal, S., & Bosserhoff, A. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5122 · Cited by 6 · see citing works

A Computational Approach to Predict the Role of Genetic Alterations in Methyltransferase Histones Genes With Implications in Liver Cancer

Aravena, T. I., Valdés-Muñoz, E., Ayala, N., & D’Afonseca, V. (2023) · Cancer Informatics · doi:10.1177/11769351231161480 · Cited by 6 · see citing works

Romidepsin hepatocellular carcinoma suppression in mice is associated with deregulated gene expression of bone morphogenetic protein and Notch signaling pathway components

Afaloniati, H., Poutahidis, T., Giakoustidis, A. E., Gargavanis, A. A., Giakoustidis, D. E., & Angelopoulou, K. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06089-9 · Cited by 6 · see citing works

Histone methyltransferase SMYD2 regulates the activation of hepatic stellate cells by activating TLR4 signaling

Ding, K.-Z., Xie, R., Han, B., Zheng, H.-L., & Tian, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-96699-9 · Cited by 7 · see citing works

Strategies to enhance the response of liver cancer to pharmacological treatments

Marı́n, J. J. G., Macı́as, R. I. R., Asensio, M., Romero, M. R., Temprano, Á. G., Pereira, O. R., Jimenez, S., Mauriz, J. L., Giacomo, S. D., Avila, M. A., et al. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00176.2024 · Cited by 6 · see citing works

PRMT1-mediated modification of H4R3me2a promotes liver cancer progression by enhancing the transcriptional activity of SOX18

Ling, J., Wang, S., Yi, C., Zheng, X., Zhou, Y., Lou, S., Li, H., Yu, R., Wu, W., Wu, Q., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000647 · Cited by 5 · see citing works

Prognosis prediction ability and prospective biological mechanisms of WDHD1 in hepatocellular carcinoma tissues

He, R., Li, J., He, W.-Y., Chen, G., Huang, Z., Li, M., Wu, W.-Z., Chen, J.-T., Pan, Y., Jiang, H., et al. (2021) · Electronic Journal of Biotechnology · doi:10.1016/j.ejbt.2021.12.001 · Cited by 5 · see citing works

Identification of differentially expressed genomic repeats in primary hepatocellular carcinoma and their potential links to biological processes and survival

Karakülah, G., & Yandım, C. (2021) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-2104-13 · Cited by 5 · see citing works

Potassium bromate toxicity and its mitigation: a mechanistic review with a transgenerational and systems toxicology outlook

Reddy, S. R., Kamarthy, P., & Manjunatha, B. (2025) · Toxin Reviews · doi:10.1080/15569543.2025.2582090 · Cited by 4 · see citing works

Progression of liver disease and associated risk of hepatocellular carcinoma

Poli, E., & Martin, E. D. (2024) · Hepatoma Research · doi:10.20517/2394-5079.2023.101 · Cited by 4 · see citing works

Fibroblasts—The emerging therapeutic target of the cardiovascular system?

Asselberghs, S., Halder, M., Kramann, R., & Sluimer, J. C. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100072 · Cited by 4 · see citing works

FGFR2–BRD4 Axis Regulates Transcriptional Networks of Histone 3 Modification and Synergy Between Its Inhibitors and PD-1/PD-L1 in a TNBC Mouse Model

Lei, J. H., Zhang, L., Wang, Z., Peltier, R., Xie, Y., Chen, G., Lin, S., Miao, K., Deng, C., & Sun, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861221 · Cited by 4 · see citing works

Dehydrocostus Lactone Reduced Malignancy of HepG2 Human Hepatocellular Carcinoma Cells via Down-Regulation of the PI3K/AKT Signaling Pathway

Gu, W., Zhao, H., Yuan, H., & Zhao, S. (2023) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-023-05708-2 · Cited by 4 · see citing works

Extrachromosomal Circular DNA: A Mobile Genetic Element Shaping Host Biology

Yao, S., Chung, O. W., Wang, L., & Zhang, Z. Z. (2025) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101323-124454 · Cited by 3 · see citing works

Histone demethylases regulate ferroptosis in metabolic dysfunction‐associated steatotic liver disease via epigenetic modification

Huang, W., Wu, W., Xiao, J., Bai, Y., Chen, C., Ou, H., Ma, Y., Que, X., Shan, S., Qu, L., et al. (2025) · FEBS Journal · doi:10.1111/febs.70351 · Cited by 3 · see citing works

Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma

Adán-Villaescusa, E., Castelló-Uribe, B., Uriarte, I., Santamaría, E., Barbero, R., Belzunce, M., López-Pascual, A., Latasa, M. U., Elurbide, J., Valbuena-Goiricelaya, E., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102717 · Cited by 3 · see citing works

Evaluation of serum ESPL1 as a biomarker for early diagnosis of HBV-related hepatocellular carcinoma

Feng, L.-H., Wei, L., Hu, B., Liang, H., Li, Q., Yin, Q., Su, T., Huang, L., Liang, H., Jiang, J., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1574317 · Cited by 3 · see citing works

Histone serotonylation in HCC: Decoding the impact of "happy" histones on liver cancer progression

Navarro‐Corcuera, A., & Martínez‐Chantar, M. L. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.020 · Cited by 3 · see citing works

Epigenetic regulation of TIPE3 in nasopharyngeal carcinoma and its impact on the hedgehog signaling pathway

Cheng, Z., Fang, Z., Yue, K., Guo, Y., Huang, L., & Zhang, Y. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05924-1 · Cited by 2 · see citing works

Identification of KRBA1 as a Potential Prognostic Biomarker Associated with Immune Infiltration and m6A Modification in Hepatocellular Carcinoma

Liu, Y., Fu, B., Yu, Z., Song, G., Zeng, H., Gong, Y., Ding, Y., & Huang, D. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s363862 · Cited by 2 · see citing works

Involvement of Epigenomic Factors in Bile Duct Cancer

Rogalska, M., & Andersen, J. B. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1748188 · Cited by 2 · see citing works

Hydroxymethylation and Epigenetic Drugs: New Insights into the Diagnosis and Treatment in Epigenetics of Hepatocellular Carcinoma

Ouyang, W., Wang, M.-D., Wang, W., Li, C., Yao, L., Zhu, H., & Yang, T. (2023) · Journal of Oncology · doi:10.1155/2023/5449443 · Cited by 2 · see citing works

A comprehensive analysis of GAS2 family members identifies that GAS2L1 is a novel biomarker and promotes the proliferation of hepatocellular carcinoma

Xu, Y., Bai, R.-X., Zhang, Q.-R., Zhang, S., Zhang, J., & Du, S. (2024) · Discover Oncology · doi:10.1007/s12672-024-01083-0 · Cited by 2 · see citing works

Senegenin suppresses hepatocellular carcinoma by regulating O-GlcNAcylation

Zhang, X., Wang, L., & Liu, Z. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i9.3994 · Cited by 2 · see citing works

Chromenopyrimidinone exhibit antitumor effects through inhibition of CAP1 (Adenylyl cyclase-associated protein 1) expression in hepatocellular carcinoma

Kim, N., Kim, S., Song, Y., Choi, I., Lee, S., Kim, K. M., Rhu, H. C., Lee, J. Y., & Seo, H. R. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110066 · Cited by 2 · see citing works

Epigenetic biomarkers in diagnosis, prognosis, and treatment of hepatocellular carcinoma

Kvaratskhelia, E., Kankava, K., Surmava, S., & Abzianidze, E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99283-1.00024-0 · Cited by 1 · see citing works

EP300 Modulates MCM8 Transcription and Augments the Malignant Phenotype of Hepatitis B Virus–Positive Hepatocellular Carcinoma Cells

Xue, F., & Sun, T. (2025) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.70006 · Cited by 1 · see citing works

Entinostat suppresses hepatocellular carcinoma metastasis by upregulating AZGP1 through histone acetylation

Cai, W., Pei, X., Ye, X., Zhai, Y., Wu, N., Wang, Z., & Lu, W. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117718 · Cited by 1 · see citing works

Crosstalk Between Cis-Regulatory Elements and Metabolism Reprogramming in Hepatocellular Carcinoma

Ren, Y., Tang, D., Ding, X., & He, M. (2026) · Cancers · doi:10.3390/cancers18061002 · Cited by 1 · see citing works

Metabolic reprogramming and the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic targeting

Ruan, Z., & Sun, X. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2025.58 · Cited by 1 · see citing works

Epigenetic dysregulation in hepatocellular carcinoma: an up‐to‐date review

Nakamura, M., Chiba, T., Kanayama, K., Kanzaki, H., Saito, T., Kusakabe, Y., & Kato, N. (2018) · Hepatology Research · doi:10.1111/hepr.13250 · Cited by 55 · see citing works

Epigenetic Changes Affecting the Development of Hepatocellular Carcinoma

Wolińska, E., & Skrzypczak, M. (2021) · Cancers · doi:10.3390/cancers13164237 · Cited by 34 · see citing works

Epigenetic therapy as a novel approach in hepatocellular carcinoma

Anestopoulos, I., Voulgaridou, G.-P., Georgakilas, A. G., Franco, R., Pappa, A., & Panayiotidis, M. I. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.09.005 · Cited by 61 · see citing works

Advances in Epigenetics of Hepatocellular CarcinomaPreprint

Liu, T., Liang, D., & Guo, C. (2024) · doi:10.22541/au.173262099.91405071/v1 · Cited by 1 · see citing works

Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics

Khan, F. S., Ali, I., Afridi, U. K., Ishtiaq, M., & Mehmood, R. (2016) · Hepatology International · doi:10.1007/s12072-016-9743-4 · Cited by 51 · see citing works